Estrella Immunopharma, Inc.
For the period ended Mar 31, 2026. Filed May 18, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 18, 2026
ESLA$0.75+45.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unaudited Condensed Consolidated Statements of Operations
| For the Three Months Ended March 31, 2026 | For the Three Months Ended March 31, 2025 | |
|---|---|---|
| Operating expenses | ||
| Research and development (including $1,375,000 for the three months ended March 31, 2026 and 2025, from related party) | $1,400,275 | $1,410,188 |
| General and administrative (including $69,946 and $ 64,433 for the three months ended March 31, 2026 and 2025, respectively, from related parties) | 891,789 | 694,110 |
| Total operating expenses | 2,292,064 | 2,104,298 |
| Loss from Operations | (2,292,064) | (2,104,298) |
| Loss before income tax | (2,292,064) | (2,104,298) |
| Income tax provision | - | (13) |
| Net loss | $(2,292,064) | $(2,104,311) |
| Net loss applicable to common stock per share, basic and diluted | $(0.05) | $(0.06) |
| Weighted average common stock outstanding, basic and diluted | 42,121,075 | 36,188,293 |
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.